Blueprint Medicines CorpNASDAQ:BPMC
- LAST PRICE105.3950
- TODAY'S CHANGE (%)1.3650 (1.3121%)
- Bid / Lots101.8800/ 1
- Ask / Lots108.9500/ 1
- Open / Previous Close103.1300 / 104.0300
- Day Range
- 52 Week Range
- Volume539,849
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BPMC |
|---|---|---|
| 09:32 ET | 2636 | 103.13 |
| 09:34 ET | 200 | 103.965 |
| 09:36 ET | 359 | 103.08 |
| 09:38 ET | 849 | 103.235 |
| 09:43 ET | 541 | 103.54 |
| 09:45 ET | 700 | 103.37 |
| 09:48 ET | 390 | 103.03 |
| 09:50 ET | 983 | 102.94 |
| 09:52 ET | 100 | 102.83 |
| 09:54 ET | 1300 | 102.69 |
| 09:56 ET | 1500 | 102.825 |
| 09:57 ET | 100 | 102.82 |
| 09:59 ET | 1617 | 102.54 |
| 10:01 ET | 1660 | 102 |
| 10:03 ET | 900 | 102.245 |
| 10:08 ET | 300 | 102.055 |
| 10:12 ET | 800 | 101.75 |
| 10:15 ET | 957 | 102 |
| 10:17 ET | 1408 | 101.92 |
| 10:19 ET | 476 | 102.1 |
| 10:21 ET | 3035 | 101.75 |
| 10:24 ET | 5583 | 102.395 |
| 10:26 ET | 200 | 102.72 |
| 10:28 ET | 2552 | 102.287 |
| 10:32 ET | 7606 | 102.47 |
| 10:33 ET | 8503 | 102.605 |
| 10:35 ET | 47300 | 102.8 |
| 10:37 ET | 200 | 102.89 |
| 10:39 ET | 800 | 102.84 |
| 10:42 ET | 3174 | 102.557 |
| 10:46 ET | 500 | 102.79 |
| 10:48 ET | 300 | 102.785 |
| 10:50 ET | 225 | 102.67 |
| 10:51 ET | 600 | 102.7 |
| 10:53 ET | 16401 | 103.14 |
| 10:55 ET | 13700 | 103.325 |
| 10:57 ET | 200 | 103.305 |
| 11:00 ET | 12954 | 103.31 |
| 11:02 ET | 100 | 103.46 |
| 11:04 ET | 1100 | 103.46 |
| 11:06 ET | 129 | 103.47 |
| 11:08 ET | 100 | 103.58 |
| 11:09 ET | 600 | 103.07 |
| 11:22 ET | 900 | 103.74 |
| 11:26 ET | 100 | 103.5 |
| 11:27 ET | 100 | 103.47 |
| 11:29 ET | 534 | 103.395 |
| 11:33 ET | 161 | 103.18 |
| 11:38 ET | 100 | 103.33 |
| 11:40 ET | 100 | 103.39 |
| 11:42 ET | 800 | 103.32 |
| 11:44 ET | 1700 | 103.14 |
| 11:54 ET | 1255 | 103.055 |
| 11:56 ET | 400 | 103.175 |
| 11:58 ET | 900 | 103.33 |
| 12:00 ET | 200 | 103.41 |
| 12:02 ET | 265 | 103.4 |
| 12:03 ET | 500 | 103.535 |
| 12:05 ET | 200 | 103.64 |
| 12:07 ET | 200 | 103.59 |
| 12:09 ET | 200 | 103.55 |
| 12:12 ET | 300 | 103.525 |
| 12:16 ET | 1400 | 103.46 |
| 12:18 ET | 400 | 103.63 |
| 12:20 ET | 1518 | 103.22 |
| 12:23 ET | 100 | 103.22 |
| 12:25 ET | 1429 | 102.91 |
| 12:32 ET | 2196 | 102.925 |
| 12:34 ET | 603 | 103.1 |
| 12:39 ET | 100 | 103.5 |
| 12:41 ET | 728 | 103.51 |
| 12:43 ET | 100 | 103.71 |
| 12:45 ET | 794 | 103.55 |
| 12:48 ET | 320 | 103.54 |
| 12:52 ET | 100 | 103.66 |
| 12:56 ET | 402 | 103.3 |
| 12:57 ET | 500 | 103.31 |
| 01:01 ET | 7600 | 103.275 |
| 01:03 ET | 600 | 103.44 |
| 01:06 ET | 100 | 103.435 |
| 01:08 ET | 100 | 103.545 |
| 01:12 ET | 200 | 103.83 |
| 01:14 ET | 711 | 103.77 |
| 01:15 ET | 100 | 103.97 |
| 01:17 ET | 100 | 103.8 |
| 01:19 ET | 100 | 103.93 |
| 01:21 ET | 200 | 103.74 |
| 01:28 ET | 100 | 103.97 |
| 01:30 ET | 100 | 104.14 |
| 01:32 ET | 901 | 104.035 |
| 01:33 ET | 900 | 103.92 |
| 01:37 ET | 100 | 104.095 |
| 01:44 ET | 300 | 104.1 |
| 01:50 ET | 200 | 104 |
| 02:00 ET | 100 | 104.265 |
| 02:02 ET | 100 | 104.13 |
| 02:04 ET | 500 | 104.37 |
| 02:06 ET | 100 | 104.475 |
| 02:09 ET | 290 | 104.695 |
| 02:11 ET | 300 | 104.67 |
| 02:13 ET | 403 | 104.82 |
| 02:15 ET | 1155 | 104.99 |
| 02:18 ET | 300 | 105.0743 |
| 02:27 ET | 200 | 104.98 |
| 02:29 ET | 100 | 105.06 |
| 02:33 ET | 400 | 105.05 |
| 02:36 ET | 700 | 105.095 |
| 02:40 ET | 100 | 105.1 |
| 02:42 ET | 400 | 105.155 |
| 02:47 ET | 200 | 105.09 |
| 02:51 ET | 300 | 104.86 |
| 02:54 ET | 100 | 104.66 |
| 02:56 ET | 1200 | 104.62 |
| 02:58 ET | 5200 | 104.72 |
| 03:00 ET | 11510 | 104.735 |
| 03:02 ET | 200 | 104.94 |
| 03:03 ET | 100 | 105.015 |
| 03:07 ET | 327 | 104.91 |
| 03:12 ET | 1389 | 104.98 |
| 03:16 ET | 600 | 104.975 |
| 03:18 ET | 9984 | 104.825 |
| 03:20 ET | 802 | 104.805 |
| 03:21 ET | 5576 | 104.715 |
| 03:23 ET | 2677 | 104.675 |
| 03:25 ET | 1945 | 104.845 |
| 03:27 ET | 273 | 104.865 |
| 03:30 ET | 5752 | 104.887 |
| 03:32 ET | 8629 | 104.52 |
| 03:36 ET | 2400 | 104.53 |
| 03:38 ET | 2088 | 104.83 |
| 03:39 ET | 4468 | 104.79 |
| 03:43 ET | 1190 | 105.02 |
| 03:45 ET | 1436 | 104.93 |
| 03:48 ET | 200 | 104.97 |
| 03:50 ET | 300 | 105.04 |
| 03:52 ET | 2715 | 105.49 |
| 03:54 ET | 2800 | 105.69 |
| 03:56 ET | 5122 | 105.72 |
| 03:57 ET | 5204 | 105.52 |
| 03:59 ET | 9996 | 105.395 |
Today
Jun 9, 2024
Jun 8, 2024
Jun 7, 2024
DJ Blueprint Medicines Price Target Maintained With a $125.00/Share by JMP Securities, from 1:24PM ET on Friday Jun 07, 2024 by Dow Jones
1:24PM ET on Friday Jun 07, 2024 by Dow JonesCurrently, The Schall Law Firm is Undertaking Probes into Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC), from 12:47PM ET on Friday Jun 07, 2024 by Dow Jones
12:47PM ET on Friday Jun 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Blueprint Medicines Corp | 6.5B | -21.9x | --- |
Revolution Medicines Inc | 6.7B | -10.4x | --- |
Viking Therapeutics Inc | 6.2B | -56.7x | --- |
Cytokinetics Inc | 6.0B | -9.9x | --- |
Legend Biotech Corp | 8.3B | -17.0x | --- |
Intra-Cellular Therapies Inc | 7.2B | -60.0x | --- |
Company Information
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Contact Information
- Headquarters
- 45 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-374-7580
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jeffrey Albers
- President, Chief Executive Officer, Director
- Kathryn Haviland
- Chief Financial Officer
- Michael Landsittel
- President - Research and Development
- Fouad Namouni
- Chief Operating Officer
- Christina Rossi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.5B |
|---|---|
Revenue (TTM) | $282.2M |
Shares Outstanding | 62.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-4.82 |
Book Value | $2.14 |
P/E Ratio | -21.9x |
Price/Sales (TTM) | 22.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -94.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
